LGND7:00 AMLigand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Millionligand.com
LGND7:00 AMLigand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Millionligand.com
LGND9:00 AMLigand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assetsligand.com